Curing cancer
by generating precision medicine
by generating precision medicine
Iscaffpharma has a deep understanding of the human tumor microenvironment and its role in creating aggressive cancer. We use this knowledge to provide:
- Target discovery and drug validation
- In-vivo like screening of drugs in human tumor models and synthetic replicas. The result is a fingerprint showing the potential effect in humans
- Personalized treatment – companion diagnostics
Iscaffpharma provides an unparalleled opportunity to improve drug development and treatment of cancer based on human cancer data.
Curing cancer
by generating precision medicine
by generating precision medicine
Iscaffpharma has deep understanding of the human tumor microenvironment and its role in creating aggressive cancer. We use this knowledge to provide in-vivo like screening of drugs in human tumor models and 3D printed replicas. The result is a fingerprint showing the potential effect in humans
This project has received funding from the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and innovation programme.
Iscaffpharmas technology reveals that breast cancer progression is influenced by tumor microenvironment
Improving cancer drug development with patient derived and synthetic scaffolds
Cancer remains a major health issue in the world affecting one third of the population and 1/5 dies from cancer.
Iscaffpharma’s mission is to establish the scaffold technology as a gold standard for cancer drug development. We also aim to develop own successful treatments for aggressive cancer using our proprietary technology with human and synthetic scaffolds that mimic true human cancer microenvironment. The over-all result being increased success rate in clinical development of cancer drugs.
Patient derived and synthetic 3D scaffold technology & analysis, how does it work?
Iscaffpharma provides analyses of cancer reporter cells for drug resistance, proliferation, differentiation, stem cell features and epithelial mesenchymal transition (EMT) in both synthetic and human scaffolds.
Selecting proteins
Human or synthetic scaffold
Synthetic scaffold mimicking human environment or De-cellularized scaffold
= Micro-environment
Repopulation with cancer cells
Understanding impact of different proteins in the environment
Analyzing
Drug resistance
Proliferation
Differentiation
Stem cell features
EMT
Products & Services
Iscaffpharmas deep understanding of the human cancer microenvironment provides unparalleled opportunities for:
-
- Target discovery and drug validation
- Drug screening in patients derived scaffolds (PDS) and synthetic replicas
- Individualized treatment and companion diagnostics
The PDS technology gives access to human relevant models in pre-clinical settings and reduces unneccesary animal experiments.
- Target discovery and drug validation
- Drug screening in patients derived scaffolds (PDS) and synthetic replicas
- Individualized treatment and companion diagnostics
Development support
Target identification
Screening of NCEs on gene expression and other factors
Licensing of technologies
3D synthetic scaffolds
Ink/Scaffold available to partners
Patient derived scaffolds
Solid tumours
Diagnostics
Precision
Personalized treatment
Liquid biopsy
Partners, Collaborators and Investors
Iscaffpharma is part of UDI3 challenge driven innovation supported by Vinnova. Our partners are:
